الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
The loss of three or more successive pregnancies before the 20th week of pregnancy is referred to as a recurrent miscarriage. There are two types: primary (in women who have never had a live birth before) and secondary (in women who have once had a live birth) (in women with at least one previous live-born infant). Abortion may be caused by a variety of causes. Even though the cause of the majority of recurrent miscarriages (50-60%) is still unknown, these include those caused by genetic abnormalities, anatomical malformations, endocrinological disorders, and immunological disorders such as antiphospholipid antibody syndrome. There is an increase in procoagulant factors and a reduction in naturally occurring anticoagulants such as protein S during pregnancy. Due to an increase in plasminogen activator inhibitor, fibrinolytic activity is reduced. All cell membranes contain omega-3 fatty acids, which serve as precursors to hormones generated locally and which are critical to human reproduction in a variety of ways. Omega-3 fatty acids are thought to influence the reproductive process in a variety of ways. The regulation of prostaglandins secretion seems to be the mechanism by which omega-3 supplementation may offer a vasodilatory impact. Omega-3 fatty acids, in particular, have been shown to improve the prostacyclin/thromboxane ratio by reducing platelet synthesis of thromboxane A2. Pregnancy outcomes may be improved by supplementing pregnant women’s diets with omega-3 fatty acids, according to a number of studies. For pregnant women, omega3 supplementation is linked to lower risks for high blood pressure and premature birth. In the family of medications known as nonsteroidal anti-inflammatory medicines, aspirin (acetylsalicylic acid) is included (NSAIDs). Analgesic, antipyretic, and antiplatelet characteristics are among the many pharmacological effects of these medicines, which have been shown to lessen inflammation. Taking 75mg of aspirin a day is enough to permanently acetylate COX-1 serine 530 and prevent platelets from producing thromboxane-A2, which has an antithrombotic effect. Pregnancy problems may be prevented with the use of low molecular weight heparin (LMWH). LMWH has been recommended as an intervention to promote placental function by boosting blood flow toward the implantation site and minimising the occurrence of thrombotic lesions. Preeclampsia, IUGR, and unexplained recurrent miscarriage may all be prevented with LMWH, which may also be an effective treatment for other placenta-mediated pregnancy problems. Because of its low molecular weight, Enoxaparin hinders the conversion of fibrinogen to fibrin and speeds up the production of anti-trypsin three and thrombin. It also causes thrombin to be inactivated. Antiphospholipid antibodies and anti-gamma interferon antibodies it bind to also have thrombo-prophylactic actions and reduce intravascular endothelial damage in the mother and trophoblast. Medical researchers at Tanta University Hospital in Egypt compared the efficacy of low dosage aspirin vs low dose aspirin plus omega 3 molecular weight-reduced supplements in the treatment of pregnant women who have recurrent, unexplained. miscarriage. group A: 20 women received a daily dose of 75mg of aspirin; group B: 20 women received a daily dose of 75mg of aspirin in addition to 300mg of omega-3 fatty acids; and group C: 20 women received a daily dose of 4000 IU of enoxaparin. All of the women in group A had unexplained recurrent miscarriages. On (5-7) weeks of pregnancy, a foetal ultrasound was performed and repeated every two weeks until the foetus reached 20 weeks of gestation. When age, BMI, gravidity, and past abortions and gestational age at enrolment were taken into account, there was no statistically significant difference between the research groups. P value = 0.583 indicated that there was no significant difference between the study groups in terms of the research outcome (completion of 20 weeks). In group A, 12 patients (60 percent) finished the 20-week study; 8 patients (40 percent) did not; 15 patients (75 percent) completed the 20-week study; 5 patients (25 percent) did not; and 14 patients (70 percent) completed the 20-week study; 6 (30 percent) did not.